These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 27592546)

  • 1. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
    Gao S; Li X; Zang J; Xu W; Zhang Y
    Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
    Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chidamide tablets: HDAC inhibition to treat lymphoma.
    Xu Y; Zhang P; Liu Y
    Drugs Today (Barc); 2017 Mar; 53(3):167-176. PubMed ID: 28447074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
    Yang S; Nan P; Li C; Lin F; Li H; Wang T; Zhou C; Zhang X; Meng X; Qian H; Wang H; Dong M
    Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV-infected patients on suppressive antiretroviral therapy.
    Li JH; Ma J; Kang W; Wang CF; Bai F; Zhao K; Yao N; Liu Q; Dang BL; Wang BW; Wei QQ; Kang WZ; Sun YT
    HIV Med; 2020 Dec; 21(11):747-757. PubMed ID: 33369029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.
    Liu L; Chen B; Qin S; Li S; He X; Qiu S; Zhao W; Zhao H
    Biochem Biophys Res Commun; 2010 Feb; 392(2):190-5. PubMed ID: 20060381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells.
    Gong K; Xie J; Yi H; Li W
    Biochem J; 2012 May; 443(3):735-46. PubMed ID: 22339555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
    Zhang N; Sun P; Jin H; Yang Y; Zhao Q; Zhou L; Guo L; Yang X; Lu L
    Anticancer Drugs; 2020 Aug; 31(7):702-708. PubMed ID: 32701251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy.
    Xie Y; Tang P; Xing X; Zhao Y; Cao S; Liu S; Lu X; Zhong L
    Spectrochim Acta A Mol Biomol Spectrosc; 2020 Nov; 241():118669. PubMed ID: 32653824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
    Dong M; Ning ZQ; Xing PY; Xu JL; Cao HX; Dou GF; Meng ZY; Shi YK; Lu XP; Feng FY
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1413-22. PubMed ID: 22362161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
    He J; Chen Q; Gu H; Chen J; Zhang E; Guo X; Huang X; Yan H; He D; Yang Y; Zhao Y; Wang G; He H; Yi Q; Cai Z
    Haematologica; 2018 Aug; 103(8):1369-1379. PubMed ID: 29773595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
    Li Y; Chen K; Zhou Y; Xiao Y; Deng M; Jiang Z; Ye W; Wang X; Wei X; Li J; Liang J; Zheng Z; Yao Y; Wang W; Li P; Xu B
    Curr Cancer Drug Targets; 2015; 15(6):493-503. PubMed ID: 26282548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application.
    Gu R; Liu T; Zhu X; Gan H; Wu Z; Li J; Zheng Y; Dou G; Meng Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Sep; 1000():181-6. PubMed ID: 26245362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells.
    Liu Z; Jing Q; Wang Y; Li Y; Mi F; Xiang C; Fu R
    Int J Mol Med; 2019 Jan; 43(1):285-293. PubMed ID: 30387821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy.
    Cao HY; Li L; Xue SL; Dai HP
    Hematol Oncol; 2023 Aug; 41(3):301-309. PubMed ID: 36251458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
    Liu Z; Ding K; Li L; Liu H; Wang Y; Liu C; Fu R
    Biomed Pharmacother; 2016 Oct; 83():1032-1037. PubMed ID: 27541047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma.
    Zhang H; Dong L; Chen Q; Kong L; Meng B; Wang H; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X
    Leuk Res; 2017 May; 56():29-35. PubMed ID: 28171799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.